Neoadjuvant camrelizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastroesophageal junction adenocarcinoma: a single-arm, phase 2 trial. The gene discussed is ERBB2; the disease is gastroesophageal junction adenocarcinoma.